

## XVIVO Perfusion – Consensus estimates Q2 2026

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 7 (all of which have been updated or confirmed before the report)

<b>KPI (MSEK, unless otherwise specified)</b>	<b>Q2 2026E</b>
Net sales	234
Organic growth in local currency (%)	33.58
Gross profit	170
EBITDA	47.9
EBIT	28.0
Net profit	21.9
Earnings per share (SEK)	0.70

XVIVO Perfusion's Q2 report will be released on Tuesday 14 July at 07.30 CEST.